Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
HEДокторантска мрежа2026–2029

CMT-DN · Tiny Machines Working to Elucidate Mechanisms of Cerebrovascular Pathologies

„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“

Период
2026-01-01 → 2029-12-31
Финансиране от ЕС
4 220 732 €
Участници
14
Схема
HORIZON-TMA-MSCA-DN

Линиите свързват координатора с партньорите.

Накратко на български

Микроскопични машини се разработват за пренос на лекарства до конкретни зони в мозъка, като се тестват върху 3D модели на мозъчни органоиди. Това помага за разбирането на механизмите при съдови заболявания на мозъка и подобрява възможностите за тяхното лечение.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Цел на проекта

The CerebroMachinesTrain Doctoral Network (CMT-DN) seeks to go beyond the state-of-the-art of drug delivery systems by focusing on tiny machines (TMs) that can be engineered as stable formulation devices capable of: i) transporting the desired amount of therapeutic substance (drug) to a target area; ii) preserving its designed function under variable physiological parameters; iii) enhancing drug bioavailability; iv) preserving the healthy environment (cells, tissues, organs) with minimal to no side effects. These TMs will require innovative engineering designs to face the complex brain environment in which they must perform as a first organ testing platform.CMT-DN aims to train and transform a young, talented generation of 14 researchers to PhD level and as future leaders in the state-of-the-art engineering of TMs and brain-on-chip devices (VRAINORG) for unravelling the mechanisms and improved treatment options underlying cerebrovascular pathologies. The engineered TMs will be designed to work and tested against VRAINORG platforms, which are 3D non-animal technologies of vascularised brain organoids (healthy and disease models) incorporated within microphysiological systems (MPs). This innovative training programme will bring together a panel of academic and industry experts in TMs biomimetic therapeutic systems and brain MPs comprising five academic and four industry partner beneficiaries, consolidated through three academic and two industry-associated partners covering nine countries across Europe and beyond, including one US associated partner. By employing these emerging non-animal technologies (i.e., vascularised brain-on-chip models), the resulting innovative therapeutic systems will benefit from facilitated clinical translation while reducing the high cost and time-consuming aspects of pre-clinical animal studies.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз